The department of clinical research and development

The department of clinical research and development

中島 淳

The department of clinical research and development contributes to the following: 1) Clinical research, 2) the development of therapy. Particularly with regard to non-alcoholic fatty liver disease (NAFLD), we organized the Japan Study Group of NAFLD (JSG-NAFLD) and has achieved remarkable accomplishments. This department engage in the development of functional foods.

Atsushi Nakajima, MD, PhD.
Chief Professor
Department of Gastroenterology and Hepatology,
Yokohama City University School of Medicine

EDUCATION:
1989 Graduated from Osaka University

Work experience:
2014 Chief Professor in Department of Gastroenterology and Hepatology,
Yokohama City University School of Medicine
1998 Visiting research fellow in Harvard University
1997 Assistant in the Third Department of Internal Medicine, Tokyo University
1994 Chigasaki Municipal Hospital
1989-1992 Internal medicine, Tokyo Yamate Medical Center (former Social Insurance General Hospital)

A member of the guideline of the nonalcoholic fatty liver disease (NAFLD) in Japan

Previous publications
Paper: 550 articles
Paper published in past 5 years (Excerpt)

  1. Clinical Gastroenterology and Hepatology, 2019
    International multi-center study on the usefulness of elastography in the diagnosis of NAFLD with 11 countries of Asia
  2. Clinical Gastroenterology and Hepatology, 2018
    The collaborative study on the magnetic resonance elastography (MRE) with Mayo Clinic
  3. Lancet Oncology. 2016
    Phase 3 trial of the preventive effect of Metformin against colorectal cancer
  4. Gastroenterology. 2016
    Clinical research on noninvasive method for diagnosis of NASH using magnetic resonance elastography (MRE)
  5. Nature. 2014
    Basic research on the protective mucosal immunity
  6. Cell Metab. 2012
    Basic research on hyperresponsivity to low-dose endotoxin



  • 患者さんとご家族のためのNAFLD/NASHガイド (日本消化器病学会編)
  • Facebook:JSG-NAFLD
  • JSG-NAFLDメンバーによる主な書籍のご紹介


  • Publications:
    • [30] Yamamura S, Nakano N, Hashida R, Tsutsumi T, Kawaguchi K, Okada M, Isoda H, Takahashi H, Matsuse H, Eguchi Y, Sumida Y, Nakajima A, Gerber L, Zobair M Younossi ZM, Torimura T. Patient-reported Outcomes (PROs) in Patients with Non-alcoholic Fatty Liver Disease: A Narrative Review of CLDQ-NAFLD/NASH. J Gastroenterol Hepatol, in press
    • [29] Sumida Y, Yoneda M, Toyoda H, Yasuda S, Tada T, Hayashi H, Yoichi Nishigaki Y, Suzuki Y, Naiki T, Morishita A, Tobita H, Sato S, Kawabe N, Fukunishi S, Ikegami T, Kessoku T, Ogawa Y, Honda Y, Nakahara T, Munekage K, Ochi T, Sawada K, Takahashi A, Arai T, Kogiso T, Kimoto S, Tomita T, Notsumata K, Nonaka M, Kawata K, Takami T, Kumada T, Tomita E, Okanoue T, Nakajima A and Japan Study Group of NAFLD (JSG-NAFLD). Common Drug Pipelines for the Treatment of Diabetic Nephropathy and Hepatopathy: Can We Kill Two Birds with One Stone? Int J Mol Sci, in press
    • [28] Fujii H, Kawada N; Japan Study Group of NAFLD (JSG-NAFLD)The Role of Insulin Resistance and Diabetes in Nonalcoholic Fatty Liver Disease.Int. J. Mol. Sci. 2020, 21(11), 3863.
    • [27] Sumida Y, Yoneda M, Yoneda M, Okanoue T, Nakajima A; Japan Study Group of NAFLD (JSG-NAFLD). Current and new pharmacotherapy options for non-alcoholic steatohepatitis. Expert Opinion On Pharmacotherapy, in press.
    • [26] Sumida Y, Okanoue T, Nakajima A; Japan Study Group of NAFLD (JSG-NAFLD). Automated quantification of fibrosis-related parameters (q-FPs) using dual-photon microscopy replace diagnosis of pathologists in NAFLD. Hepato Biliary Surgery and Nutrition, in press.
    • [25] Sumida Y, Yoneda M, Tokushige K, Kawanaka M, Fujii H, Yoneda M, Imajo K, Takahashi H, Eguchi Y, Ono M, Nozaki Y, Hyogo H, Koseki M, Yoshida Y, Kawaguchi T, Kamada Y, Okanoue T, Nakajima A, Atsushi Nakajima; Japan Study Group of NAFLD (JSG-NAFLD). Antidiabetic therapy in the treatment of nonalcoholic steatohepatitis. Inter J Mol Sci 2020;21 (6),1907.
    • [24] Sumida Y, Yoneda M, Tokushige K, Kawanaka M, Fujii H, Yoneda M, Imajo K, Takahashi H, Eguchi Y, Ono M, Nozaki Y, Hyogo H, Koseki M, Yoshida Y, Kawaguchi T, Kamada Y, Okanoue T, Nakajima A; Japan Study Group of NAFLD (JSG-NAFLD). Hepatoprotective Effect of SGLT2 Inhibitor on Nonalcoholic Fatty Liver Disease. Diab Res. 2020 Mar 05;2(S1):17-25.
    • [23] Sumida Y, Yoneda M, Tokushige K, Kawanaka M, Fujii H, Yoneda M, Imajo K, Takahashi H, Eguchi Y, Ono M, Nozaki Y, Hyogo H, Koseki M, Yoshida Y, Kawaguchi T, Kamada Y, Okanoue T, Nakajima A; Japan Study Group of NAFLD (JSG-NAFLD). Estimated Prevalence of Advanced Hepatic Fibrosis by Elastography in Patients with Type 2 Diabetes. Interventions Obes Diabetes 3(3). IOD.000570.2020. DOI: 10.31031/IOD.2020.03.000570
    • [22] Sumida Y, Yoneda M, Tokushige K, Kawanaka M, Fujii H, Yoneda M, Imajo K, Takahashi H, Eguchi Y, Ono M, Nozaki Y, Hyogo H, Koseki M, Yoshida Y, Kawaguchi T, Kamada Y, Okanoue T, Nakajima A; Japan Study Group of NAFLD (JSG-NAFLD). Antidiabetic Treatments for Diabetes with Liver Cirrhosis. Interventions Obes Diabetes 3(3). IOD.000566.2020. DOI: 10.31031/IOD.2020.03.000566
    • [21] Sumida Y, Okanoue T, Nakajima A; Japan Study Group of NAFLD (JSG-NAFLD). Phase 3 drug pipelines in the treatment of non-alcoholic steatohepatitis. Hepatol Res. 2019 Nov;49(11):1256-1262. doi: 10.1111/hepr.13425. Epub 2019 Oct 25.
    • [20] Sumida Y, Yoneda M, Okanoue T; Japan Study Group of Non-Alcoholic Fatty Liver Disease (JSG-NAFLD). Is the grade of ballooned hepatocytes a significant risk factor for rapid progression of hepatic fibrosis in patients with NAFLD? J Gastroenterol. 2019 May;54(5):474-475.
    • [19] Fujii H, Imajo K, Yoneda M, Nakahara T, Hyogo H, Takahashi H, Hara T, Tanaka S, Sumida Y, Eguchi Y, Chayama K, Nakajima A, Nishimoto N, Kawada N; Japan Study Group of Nonalcoholic Fatty Liver Disease. HOMA-IR: An independent predictor of advanced liver fibrosis in nondiabetic non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2019 Aug;34(8):1390-1395.
    • [18] Ishiba H, Sumida Y, Tanaka S, Yoneda M, Hyogo H, Ono M, Fujii H, Eguchi Y, Suzuki Y, Yoneda M, Takahashi H, Nakahara T, Seko Y, Mori K, Kanemasa K, Shimada K, Imai S, Imajo K, Kawaguchi T, Nakajima A), Chayama K, Saibara T, Shima T, Fujimoto K, Okanoue T, Itoh Y; Japan Study Group of Non-Alcoholic Fatty Liver Disease (JSG-NAFLD). The novel cutoff points for the FIB4 index categorized by age increase the diagnostic accuracy in NAFLD: a multi-center study.J Gastroenterol. 2018 Nov;53(11):1216-1224. doi: 10.1007/s00535-018-1474-y. Epub 2018 May 9.
    • [17] Kawaguchi T, Tokushige K, Hyogo H, Aikata H, Nakajima T, Ono M,Kawanaka M, Sawada K, Imajo K, Honda K, Takahashi H, Mori K,Tanaka S(12), Seko Y, Nozaki Y, Kamada Y, Fujii H, Kawaguchi A, Takehara T, Yanase M, Sumida Y, Eguchi Y, Seike M,Yoneda M, Suzuki Y, Saibara T, Karino Y, Chayama K, Hashimoto E, George J, Torimura T. A Data Mining-based Prognostic Algorithm for NAFLD-related Hepatoma Patients: A Nationwide Study by the Japan Study Group of NAFLD. Sci Rep. 2018 Jul 11;8(1):10434. doi: 10.1038/s41598-018-28650-0.
    • [16] Kamada Y, Ono M, Hyogo H, Fujii H, Sumida Y, Yamada M, Mori K, Tanaka S, Maekawa T, Ebisutani Y, Yamamoto A, Takamatsu S, Yoneda M, Kawada N, Chayama K, Saibara T, Takehara T, Miyoshi E; Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG‐NAFLD). Use of Mac-2 binding protein as a biomarker for nonalcoholic fatty liver disease diagnosis. Hepatol Commun. 2017 Aug 16;1(8):780-791.
    • [15] Sumida Y, Seko Y, Yoneda M; Japan Study Group of NAFLD (JSG-NAFLD). Novel antidiabetic medications for non-alcoholic fatty liver disease with type 2 diabetes mellitus. Hepatol Res. 2017 Mar;47(4):266-280.
    • [14] Oeda S, Takahashi H, Yoshida H, Ogawa Y, Imajo K, Yoneda M, Koshiyama Y, Ono M, Hyogo H, Kawaguchi T, Fujii H, Nishino K, Sumida Y, Tanaka S, Kawanaka M, Torimura T, Saibara T, Kawaguchi A, Nakajima A, Eguchi Y; Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD). Prevalence of pruritus in patients with chronic liver disease: A multicenter study. Hepatol Res. 2017 Sep 6. doi:10.1111/hepr.12978. [Epub ahead of print] PubMed PMID: 28877392.
    • [13] Sumida Y, Nakajima A, Hyogo H, Tanaka S, Japan Study Group of NAFLD (JSG-NAFLD), et al. (2015) Non-invasive scoring systems for predicting NASH in Japan: evidences from Japan Study Group of NAFLD. Integr Mol Med 2: DOI: 10.15761/IMM.1000130
    • [12] Kessoku T, Yoneda M, Sumida Y, Eguchi Y, Fujii H, Hyogo H, Ono M, Kawaguchi T, Nakajima A; Japan Study Group of NAFLD. Insulin resistance correlated with the severity of liver histology in Japanese NAFLD patients: a multicenter retrospective study. J Clin Gastroenterol. 2015 Feb;49(2):169-70.
    • [11] Eguchi Y, Kitajima Y, Hyogo H, Takahashi H, Kojima M, Ono M, Araki N, Tanaka K, Yamaguchi M, Matsuda Y, Ide Y, Otsuka T, Ozaki I, Ono N, Eguchi T, Anzai K; Japan Study Group for NAFLD (JSG-NAFLD). Pilot study of liraglutide effects in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN-J). Hepatol Res. 2015 Mar;45(3):269-78.
    • [10] Nakahara T, Hyogo H, Yoneda M, Sumida Y, Eguchi Y, Fujii H, Ono M, Kawaguchi T, Imajo K, Aikata H, Tanaka S, Kanemasa K, Fujimoto K, Anzai K, Saibara T, Sata M, Nakajima A, Itoh Y, Chayama K, Okanoue T; Japan Study Group of Nonalcoholic Fatty Liver Disease. Type 2 diabetes mellitus is associated with the fibrosis severity in patients with nonalcoholic fatty liver disease in a large retrospective cohort of Japanese patients. J Gastroenterol. 2014 Nov;49(11):1477-84.
    • [9] Kessoku T, Ogawa Y, Yoneda M, Imajo K, Sumida Y, Eguchi Y, Fujii H, Hyogo H, Ono M, Suzuki Y, Kawaguchi T, Chayama K, Tanaka S, Fujimoto K, Anzai K, Saibara T, Sata M, Itoh Y, Nakajima A, Okanoue T; Japan Study Group of NAFLD (JSG-NAFLD). Simple scoring system for predicting cirrhosis in nonalcoholic fatty liver disease. World J Gastroenterol. 2014 Aug 7;20(29):10108-14.
    • [8] Taketani H, Sumida Y, Tanaka S, Imajo K, Yoneda M, Hyogo H, Ono M, Fujii H, Eguchi Y, Kanemasa K, Chayama K, Itoh Y, Yoshikawa T, Saibara T, Fujimoto K, Nakajima A; Japan Study Group of NAFLD. The association of insomnia with gastroesophageal reflux symptoms in biopsy-proven nonalcoholic fatty liver disease. J Gastroenterol. 2014 Jul;49(7):1163-74.
    • [7] Tanaka K, Hyogo H, Ono M, Takahashi H, Kitajima Y, Ono N, Eguchi T, Fujimoto K, Chayama K, Saibara T, Anzai K, Eguchi Y; Japan Study Group of Non-alcoholic Fatty Liver Disease (JSG-NAFLD). Upper limit of normal serum alanine aminotransferase levels in Japanese subjects. Hepatol Res. 2014 Nov;44(12):1196-207.
    • [6] Yoneda M, Imajo K, Eguchi Y, Fujii H, Sumida Y, Hyogo H, Ono M, Suzuki Y, Kawaguchi T, Aoki N, Sata M, Kanemasa K, Kohgo Y, Saibara T, Chayama K, Itoh Y, Yoshikawa T, Anzai K, Fujimoto K, Okanoue T, Nakajima A; Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD). Noninvasive scoring systems in patients with nonalcoholic fatty liver disease with normal alanine aminotransferase levels. J Gastroenterol. 2013 Sep;48(9):1051-60.
    • [5] Kitajima Y, Hyogo H, Sumida Y, Eguchi Y, Ono N, Kuwashiro T, Tanaka K, Takahashi H, Mizuta T, Ozaki I, Eguchi T, Kimura Y, Fujimoto K, Anzai K; Japan Nonalcoholic Fatty Liver Disease Study Group (JSG-NAFLD). Severity of non-alcoholic steatohepatitis is associated with substitution of adipose tissue in skeletal muscle. J Gastroenterol Hepatol. 2013 Sep;28(9):1507-14.
    • [4] Sumida Y, Yoneda M, Hyogo H, Itoh Y, Ono M, Fujii H, Eguchi Y, Suzuki Y, Aoki N, Kanemasa K, Fujita K, Chayama K, Saibara T, Kawada N, Fujimoto K, Kohgo Y, Yoshikawa T, Okanoue T; Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD). Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population. BMC Gastroenterol. 2012 Jan 5;12:2.
    • [3] Eguchi Y, Hyogo H, Ono M, Mizuta T, Ono N, Fujimoto K, Chayama K, Saibara T;JSG-NAFLD. Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study. J Gastroenterol. 2012 May;47(5):586-95.
    • [2] Yoneda M, Fujii H, Sumida Y, Hyogo H, Itoh Y, Ono M, Eguchi Y, Suzuki Y, Aoki N, Kanemasa K, Imajo K, Chayama K, Saibara T, Kawada N, Fujimoto K, Kohgo Y, Yoshikawa T, Okanoue T; Japan Study Group of Nonalcoholic Fatty Liver Disease. Platelet count for predicting fibrosis in nonalcoholic fatty liver disease. J Gastroenterol. 2011 Nov;46(11):1300-6.
    • [1] Sumida Y, Yoneda M, Hyogo H, Yamaguchi K, Ono M, Fujii H, Eguchi Y, Suzuki Y, Imai S, Kanemasa K, Fujita K, Chayama K, Yasui K, Saibara T, Kawada N, Fujimoto K, Kohgo Y, Okanoue T; Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD). A simple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease. J Gastroenterol. 2011 Feb;46(2):257-68.